Shots:

• Wigen to transfer its 50% interest in four drugs WJ1024/WJ1075- WJ05129- APL1898- and WJ13404 to Junshi. Wigen to receive $5.3M up front- $64.3M as milestones- and 50% on the net profit of the therapies
• Junshi to get WW exclusive rights for the production and commercialization of these drugs and will be responsible for clinical trial applications. The companies will jointly facilitate the pre-clinical research work of the therapies
• WJ1024/WJ1075 is an XPO1 inhibitor- WJ05129 is an Aurora-A inhibitor- APL1898 is an EGFR-exon20 inhibitor while the last drug is an effective fourth-generation EGFR inhibitor

­ Ref: PRNewswire | Image: Wigen